

PRESS RELEASE

Metagen Therapeutics Presents Latest Research at Microbiome Movement, the World's Largest Microbiome Conference, and Other Major Conferences

Showcasing our progress of "gut microbiome therapy" research in Japan

Yamagata, Japan, July 4, 2023—Metagen Therapeutics Inc. (President & CEO: Taku Nakahara, PhD), a company focusing on drug discovery and development with intestinal microbiome-based therapeutics for various diseases, was invited to make a presentation at the 8th Microbiome Movement, the world's largest microbiome conference, held in Boston, U.S. from June 28 to 30, 2023.

Presentation included the clinical development of Fecal Microbiota Transplants (FMT) in Japan. Metagen Therapeutics also participated in a panel discussion with FDA Principal Investigator Paul Carlson and other panelists to discuss regulations on microbiome therapies and drug development in various countries.



Presentation by CEO Nakahara



Lecture by CSO Terauchi

Metagen Therapeutics have been making a global presence recently, participating in the following international microbiome conferences, presenting original research on gut microbiome therapy in Japan.

■ 8th Microbiome Movement, Boston, USA, June 28-30, 2023

•Clinical Development of Fecal Microbiota Transplantation for Ulcerative Colitis in Japan (Taku Nakahara, Co-founder & CEO, Metagen Therapeutics, Inc.)

International Spotlight: A new initiative for Microbiome Based Drug Discovery Ecosystem Creation in Japan as one of Government Funded Programs

(Jun Terauchi, Chairman of Steering Committee, Japan Microbiome Consortium / Director and CSO, Metagen Therapeutics, Inc.)

•Panel Discussion -Global Regulatory Perspectives: US, Asia & Europe Perspectives

- Paul Carlson, Principal Investigator, FDA
- Jun Terauchi, Chairman of Steering Committee, Japan Microbiome Consortium / Director, CSO, Metagen Therapeutics, Inc.
- Clara Desvignes, Director, Drugs, Medical Devices & Microbiome Based Products, VCLS



Panel discussion, seated from left, Desvignes, Terauchi, Carlson

■ May 16-17, 2023 Microbiome Connect ASIA 2023 (Seoul, Korea)

• Microbiome Drug Discovery Based On Intestinal Flora Transplantation (FMT)

(Taku Nakahara, Co-founder & CEO, Metagen Therapeutics, Inc.)



•Japanese Precompetitive Initiatives To Promote Microbiome-based Drug Discovery In Japan

(Jun Terauchi, Chairman of Steering Committee, Japan Microbiome Consortium / Director and CSO, Metagen Therapeutics, Inc.)

■ 6th Annual Conference of Taiwan Microbiota Consortium 2023 (Taiwan, online participation)

•Recent Trends in Microbiome Based Drug Discovery Activities in Japan

(Jun Terauchi, Chairman of Steering Committee, Japan Microbiome Consortium / Director and CSO, Metagen Therapeutics, Inc.)

■ March 21-22, 2023 Pharmabiotics 2023 (Lyon, France)

•Challenges, Efforts and Initiatives to Promote Microbiome-based Drug Discovery in Japan

(Jun Terauchi, Chairman of Steering Committee, Japan Microbiome Consortium / Director and CSO, Metagen Therapeutics, Inc.)



Metagen Therapeutics continues to publish information to the world as a leading company in medicine and drug discovery based on intestinal bacteria research in Japan.

What is a microbiome?

A microbiome refers to the community of bacteria present throughout the human body including the intestines, skin and mouth. There are known to be approximately 40 trillion* bacterial cells in the human intestine, and in recent years, it has become evident to have significant impact on human health.

* Sender, R., Fuchs, S. & Milo, R. Revised Estimates for the Number of Human and Bacteria Cells in the Body. *PLoS Biol.* 14, e1002533 (2016)

What is FMT?

FMT refers to the transplantation of intestinal microbiota from the stool of healthy individuals into the intestines of patients using a colonoscope. This is a medical technology and procedure that improves dysbiosis, the imbalance of the microbiota. Clinical research began in 2014, and Juntendo University has accumulated a track record of FMT in more than 200 patients** with ulcerative colitis, publishing research papers and case studies internationally in a number of top journals.

**https://www.juntendo.ac.jp/hospital/clinic/shokaki/about/treatment/intestinal_microbiota1.html

About Metagen Therapeutics

Metagen Therapeutics is a biotech startup founded by researchers of Juntendo University, Keio University and Tokyo Institute of Technology in 2020 with the mission of “Living up to the hopes of patients through microbiome science”. The company has been accelerating its drug discovery and development work on intestinal microbiome-based therapeutics for various diseases such as cancer, ulcerative colitis, and Parkinson’s disease. It aims for social impact through medical care and drug discovery.

For more information, go to <https://www.metagentx.com> or follow us on LinkedIn at <https://www.linkedin.com/company/metagentx/>.

For press inquiries or investor inquiries, please email: pr@metagentx.com

<Company Profile>

Metagen Therapeutics Inc.

President and CEO : Taku Nakahara, PhD

Founded: January 17, 2020

Head Office : 246-2 Minakami, Kakuganji, Tsuruoka City, Yamagata Prefecture

Tokyo Office : Toranomon Hills Business Tower 15th Floor, 1-17-1 Toranomon, Minato-ku, Tokyo

Main Business: Drug discovery and medical business through microbiota therapeutics